fda green list glp-1 import alert 66-80 The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome NFNUTRI_BOGO50_AUG26 Technologies enabling long-term health Dose:FOUNDAYO 17.2MG

fda green list glp-1 import alert 66-80 The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome NFNUTRI_BOGO50_AUG26 Technologies enabling long-term health Dose:FOUNDAYO 17.2MG

Technologies enabling long-term health outcomes for GLP-1 users

Aleniglipron looks like a credible oral alternative to injectable GLP-1 drugs, with comparable weight loss to existing options

NFNUTRI_BOGO50_AUG26

Dose:FOUNDAYO 17.2MG

Mounjaro’s additional action on GIP receptors is thought to be part of why it tends to produce somewhat greater average weight loss in trials, which we look at below